证券代码：300244 证券简称：迪安诊断 公告编号：2025-006 迪安诊断技术集团股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 21 日 14 点，迪安诊断技术集团股份有限公司（以下简称"公 司"或"迪安诊断"）以通讯表决的方式召开了第五届监事会第九次会议。召开 本次会议的通知已于 2025 年 4 月 11 日以短信、电子邮件等方式通知全体监事。 会议由公司监事会主席师玉鹏先生召集和主持。本次监事会应到监事 3 名，实到 监事 3 名，符合《公司法》和《公司章程》的规定，会议通过了如下决议： 一、审议《关于<2024年度监事会工作报告>的议案》 具体内容详见公司于同日在巨潮资讯网披露的《2024 年度监事会工作报 告》。 该议案尚需提交股东大会审议。 三、审议《关于<2024年年度报告>及<2024年年度报告摘要>的议案》 经审议，监事会认为：公司 2024 年年度报告及摘要的编制和审核符合法律 法规和相关制度的有关规定，报告内容真实、准确、完整的反映了上市公司的财 务状况、经营成果 ...

迪安诊断技术集团股份有限公司 2024 年年度报告全文 迪安诊断技术集团股份有限公司 2024 年年度报告 2025 年 4 月 1 迪安诊断技术集团股份有限公司 2024 年年度报告全文 2024 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人陈海斌、主管会计工作负责人赵德康及会计机构负责人(会计主管人员)赵 德康声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、报告期，基于市场需求增长放缓、行业竞争加剧以及公司战略性放弃亏损或回款 周期较长业务等因素，公司短期整体营业收入承压，相应利润空间亦被一定挤压。同时， 公司加大重点疾病线检验项目的研发投入，推进高端技术平台的能力建设和专业人才的引 进，开拓广东及越南等新兴市场业务，上述基于长期主义的投入尚在培育期，对公司利润 有一定影响。 2、报告期，因部分应收款项回款周期有所延长，年度计提坏账准备的金额共计 48,725.32 万元。 3、报告期，基于因行业 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2025-005 具体内容详见公司于同日在巨潮资讯网披露的《2024 年年度报告》的第三 节"管理层讨论与分析"章节。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议《关于<2024年度董事会工作报告>的议案》 具体内容详见公司于同日在巨潮资讯网披露的《2024 年年度报告》。 第五届独立董事李天天先生、邓泽林先生、蒋斌先生分别向董事会提交了《独 立董事 2024 年度述职报告》，并将在 2024 年年度股东大会上进行述职。 迪安诊断技术集团股份有限公司 表决结果：同意 9 票，反对 0 票，弃权 0 票。 第五届董事会第十二次会议决议公告 该议案尚需提交股东大会审议。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 21 日 19 时，迪安诊断技术集团股份有限公司（以下简称"公 司"或"迪安诊断"）以通讯表决的方式召开了第五届董事会第十二次会议。召 开本次会议的通知已于 2025 年 4 月 11 日以短信、电子邮件等方式通知全体董事。 会议由公司董事长陈海斌先生召集 ...

4月9日，迪安诊断今日收盘13.7元，上涨2.85%，最新市净率1.21，总市值85.62亿元。 资金流向方面，4月9日，迪安诊断主力资金净流出33.97万元，近5日总体呈流出状态，5日共流出 9653.84万元。 迪安诊断技术集团股份有限公司的主营业务是医学诊断服务及体外诊断产品销售。公司的主要产品及服 务是医学诊断服务、诊断技术研发、诊断产品生产及销售、CRO、司法鉴定、健康管理。2023年，公 司获得了浙江省人民政府质量奖等荣誉。 最新一期业绩显示，2024年三季报，公司实现营业收入92.58亿元，同比-10.05%；净利润1.31亿元，同 比-75.35%，销售毛利率28.05%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)3迪安诊断-92.5027.851.2185.62亿行业平均 45.7741.333.33140.72亿行业中值43.7835.472.4544.48亿1普瑞眼科-192.3424.042.9064.41亿2何氏眼 科-144.5344.311.4628.16亿4光正眼科-84.88201.676.8418.66亿5创新医疗-78.10-109.142.0337.42亿 ...

Core Viewpoint - The company, Dian Diagnostics, is recognized as a leading third-party medical diagnostics enterprise in China, with a significant accumulation of medical data and a leading position in the application of this data in the healthcare sector [2]. Group 1: Company Performance - As of March 28, 2025, Dian Diagnostics' stock closed at 15.88 yuan, down 1.12%, with a turnover rate of 3.04%, a trading volume of 152,400 shares, and a transaction value of 244 million yuan [1]. - On the same day, the net inflow of main funds was 6.45 million yuan, accounting for 2.64% of the total transaction value [3]. Group 2: Strategic Initiatives - The company is focused on integrating cutting-edge technologies, including robotics and brain-computer interface applications, into its diagnostic services to enhance efficiency and precision for patients [2]. - In 2024, the company repurchased nearly 200 million yuan worth of stock, with plans for stock incentive programs or potential cancellation [2].

Summary of the Conference Call Company and Industry - **Company**: Di'an Diagnostics - **Industry**: AI in Medical Diagnostics Key Points and Arguments 1. **AI Medical Business Layout**: Di'an Diagnostics has been focusing on AI in the medical field, particularly in diagnostics and treatment, since 2021 with the establishment of a subsidiary, Yice Technology, specializing in AI pathology [1][2][3] 2. **Product Development**: The company has developed several AI products, including a cervical cancer diagnostic tool that received a Class II medical certification in 2023 and is expected to obtain a Class III certification by June 2023 [3][4] 3. **Market Penetration**: Di'an has signed contracts with approximately 70 local hospitals in Hubei Province, achieving over 50% market share in the digital pathology service system [3][4] 4. **AI Models**: The company has created a proprietary AI model called the Di'an Vertical Model, which is currently under review for official recognition [5][6] 5. **Collaboration with Hospitals**: Di'an collaborates with hospitals, such as Wuhan Union Hospital, to develop predictive models for chronic leukemia treatment, which have gained recognition both domestically and internationally [6][7] 6. **Health Management Initiatives**: Di'an has partnered with Huawei Cloud to enhance health management services, allowing users to upload health reports for risk assessments and personalized recommendations [7][8] 7. **Data Accumulation**: The company has accumulated 5.4 PB of valuable data from approximately 160 million tests conducted annually, with a growth rate of about 100 TB per month [16][17] 8. **Clinical Research Database**: Di'an has launched a clinical research database in collaboration with major hospitals, integrating clinical data with multi-omics data for research purposes [17][18] 9. **Regulatory Compliance**: The company has obtained various certifications for data security and compliance, enhancing its credibility in the data management sector [18][19] 10. **Future Business Opportunities**: Di'an plans to commercialize its AI tools through various channels, including diagnostic testing packages, clinical decision support tools, and smart laboratory products [14][15][20] Additional Important Content 1. **Competitive Landscape**: Di'an acknowledges competition in the AI pathology space, particularly from partnerships like that of Huawei and Ruijin Hospital, but emphasizes its unique data advantages and focus on clinical applications [22][23] 2. **Differentiation in AI Models**: Di'an's AI models are tailored for specific diseases, leveraging extensive data for productization, which sets them apart from competitors focusing on broader applications [24][25] 3. **Market Trends**: The company is observing interest from other provinces in replicating Hubei's digital pathology model, indicating potential for expansion [25][26] 4. **Data Annotation Team**: The company is expanding its data annotation team to manage the increasing volume of data, which is crucial for training AI models [35]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 迪安诊断技术集团股份有限公司（以下简称"公司"或"迪安诊断"）股票连 续三个交易日内（2025年2月13日、2月14日、2月17日）收盘价格涨幅偏离值累计达 到30%以上，根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动 情形。 证券代码：300244 证券简称：迪安诊断 公告编号：2025-003 迪安诊断技术集团股份有限公司 关于股票交易异常波动的公告 公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票上市规 则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、 协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市规则》等 有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生较大影 响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 1. 经自查，公司不存在违反信息公平披露的情形。 二、公司关注并核实相关情况 针对公司股票异常波动情况，公司董事会通过电话、现场等问询方式，对相关 问题进行了 ...

Summary of Conference Call Company and Industry Involved - The conference call primarily discusses the advancements and strategies of a company involved in medical diagnostics, particularly focusing on AI applications in pathology and health management. Key Points and Arguments AI in Diagnostics and Treatment - The company is leveraging AI technology in pathology to enhance drug development processes, particularly in clinical testing and analysis [1] - Collaborations with leading hospitals, such as Huazhong University of Science and Technology, are aimed at developing predictive models for chronic diseases like chronic leukemia [2] - The company has established a Chronic Leukemia Discontinuation Alliance to promote predictive models in treatment [3] - A strategic partnership with Huawei focuses on AI health management, utilizing health data to generate risk assessments for major diseases [4] Health Management Applications - The AI health management system aims to provide personalized health promotion and risk assessments based on individual health data [5] - The company is developing a comprehensive AI-driven health management tool that can be utilized by both patients and healthcare providers [11] Data and AI Model Development - The company has built a robust data platform that integrates extensive medical testing data for AI training and model development [8] - A new AI model named "启迪索威" is being developed, focusing on multi-modal applications in medical diagnostics [10] - The company emphasizes the importance of data quality and governance in AI model training, having processed approximately 60 million valuable samples for research and AI learning [14] Market Strategy and Commercialization - The company has signed agreements with over 70 hospitals in Hubei for AI pathology services, achieving a market share of approximately 70% in that region [29] - The pricing strategy for AI pathology services is competitive, with costs ranging from 60 to 300 RMB per test, reflecting the value of AI in enhancing diagnostic accuracy [44] - The company aims to expand its market presence by promoting AI solutions in collaboration with government initiatives and healthcare institutions [19][20] Future Outlook - The company is optimistic about the growth of AI applications in healthcare, particularly in diagnostics and health management, as the technology becomes more accessible [40] - There is a focus on developing digital products as part of a five-year strategic plan, with an emphasis on integrating AI into existing healthcare solutions [41] Challenges and Industry Dynamics - The medical diagnostics industry is experiencing significant changes, with a notable number of companies exiting the market, leading to increased competition and consolidation [49] - The company is prepared to adapt to regulatory changes and market demands, ensuring compliance and maintaining a competitive edge [48] Other Important but Overlooked Content - The company has a dedicated AI research team, including experts from various fields, to enhance its technological capabilities [6] - There is a strong emphasis on collaboration with external experts and institutions to drive innovation in AI applications [7] - The company is also exploring the potential for data monetization through compliance with legal and regulatory standards [16][17] This summary encapsulates the key discussions and insights from the conference call, highlighting the company's strategic initiatives, market positioning, and future outlook in the medical diagnostics industry.

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% [5][10]. Core Insights - The company is expected to report a net loss of RMB 270 million to 370 million in 2024, primarily due to significant impairment losses on receivables and goodwill [8]. - The company is building an AI ecosystem for diagnostic and treatment services, leveraging its own computing power and cloud resources [8]. - The forecasted net profits for 2024, 2025, and 2026 are RMB -340 million, RMB 650 million, and RMB 720 million, respectively, with an expected EPS of RMB -0.55, RMB 1.03, and RMB 1.15 [8]. Financial Summary - The company's revenue is projected to decline from RMB 12,172 million in 2023 to RMB 12,741 million in 2025, before increasing to RMB 13,317 million in 2026 [13]. - The net profit for 2023 is expected to be RMB 307 million, with a significant drop to RMB -344 million in 2024, followed by a recovery in subsequent years [7][13]. - The company's total assets are expected to decrease from RMB 17,939 million in 2023 to RMB 16,485 million in 2024, before gradually increasing to RMB 19,466 million by 2026 [13].

Summary of the Conference Call Company and Industry Overview - The conference call focused on **Dian Diagnostics**, a comprehensive medical diagnostic service provider, discussing its advancements in **AI** and future commercialization prospects in the healthcare industry [1][2]. Key Points and Arguments AI Development and Applications - Dian has established a specialized AI company, **Yicai Technology**, focusing on pathology, leveraging over **100,000 pathology samples** for AI applications [2][3]. - In **2023**, Dian obtained a Class II medical device certification for its digital products and is in the process of acquiring a Class III certification, expected by **June 2025** [3]. - The company has partnered with **70+ local hospitals** in Hubei to create a digital pathology service system, achieving a **70%** implementation rate in the region [3]. - Over **3 million AI pathology diagnostic reports** have been provided to various hospitals and clients [3]. Treatment Innovations - A strategic collaboration with **Wuhan Tongji Medical College** focuses on developing a predictive model for chronic myeloid leukemia (CML) treatment, which has been presented at the **American Society of Hematology** [4][5]. - The predictive model aims to determine whether patients can reduce or stop medication, enhancing treatment efficiency and reducing costs [5][36]. Health Management and Personalized Medicine - Dian is integrating AI into personalized healthcare management, utilizing health data from wearable devices and health reports to generate health promotion documents and risk assessments [6][7]. - The company is developing precision diagnosis centers in collaboration with hospitals to enhance personalized medical services [6]. AI Ecosystem and Team Development - Dian has built a robust AI ecosystem, including a team led by **Dr. Wang Yu**, previously from Alibaba's DAMO Academy, focusing on medical imaging AI [8][9]. - The AI infrastructure includes partnerships with **Huawei** and **Alibaba Cloud** for computational resources, and a proprietary big data platform with nearly **60 million samples** for disease and discipline tagging [10][15]. Data Security and Compliance - Dian has received certifications for data security management, including **ISO 27001** and **DSM**, ensuring compliance with data protection regulations [17][18]. - The company emphasizes the importance of data quality and quantity in AI model development, with a focus on maintaining patient privacy and data security [49]. Commercialization Strategies - Dian's AI business model includes various revenue streams, such as AI-enhanced diagnostic products, health management tools, and data services for healthcare institutions [31][34]. - The company is exploring partnerships with external software providers to integrate AI tools into healthcare practices [32]. Future Outlook - The management expressed optimism about the future growth of AI applications in healthcare, emphasizing the potential for AI to enhance existing services and create new business opportunities [40][54]. - The focus remains on leveraging Dian's unique data resources and industry expertise to drive innovation and improve patient outcomes [53][54]. Other Important but Overlooked Content - The call highlighted the challenges of AI implementation in healthcare, including the need for significant computational resources and the fragmentation of medical data across various institutions [51][52]. - There is a recognition of increasing competition in the AI healthcare space, prompting Dian to focus on its unique strengths and customer base [53]. This summary encapsulates the key discussions and insights from the conference call, providing a comprehensive overview of Dian Diagnostics' current position and future strategies in the AI healthcare landscape.